Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024
Logotype for Neuronetics Inc

Neuronetics (STIM) Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary

Event summary combining transcript, slides, and related documents.

Logotype for Neuronetics Inc

Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary

2 Feb, 2026

Company overview and market opportunity

  • FDA-cleared transcranial magnetic stimulation device for depression, with 6.6 million treatments delivered to 182,000 patients.

  • Devices are used in nearly 1,200 centers, with about 2,300 systems in the field and reimbursement from all major payers.

  • Market opportunity remains large, with 4.4 million patients who have failed four drugs, and awareness of TMS has doubled to 18% in four years.

  • The Better Me Provider program has improved patient response times and increased business for participating practices by 61%.

  • Recent FDA clearance for adolescent treatment (ages 15-21) positions the company as a first-line therapy for this group.

Financial performance and guidance

  • Q3 revenue projected at $18.5–$19.5 million, with full-year guidance of $78–$80 million; third consecutive year of revenue growth and OpEx reduction.

  • Acquisition of Greenbrook TMS expected to add $74 million in revenue, with combined 2023 revenues projected at $143 million and $50 million in debt.

  • Cost synergies of $15 million identified, in addition to $23 million in cost reductions already achieved by Greenbrook.

  • New debt facility with Perceptive Advisors provides financial flexibility, with a $140 million debt conversion to stock at close.

  • Targeting cash flow breakeven in 2025, supported by improved cap structure and operational discipline.

Strategic rationale and integration benefits

  • Acquisition of Greenbrook TMS expands scale to 350 centers in 49 states, enhancing payer negotiations and reimbursement rates.

  • Consistent training and branding across 120 new centers expected to drive patient growth and franchise effect.

  • Access to Greenbrook’s call center and contracts improves practice economics and reduces reimbursement wait times.

  • Revenue synergies expected from expanded med management and Spravato offerings, and unified branding.

  • Marketing OpEx to be reduced from $21 million to $15 million without impacting customer economics.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Neuronetics